The objective of the study was to compare the efficacy of combination containing Metformin plus Sulfonylureas (MET+GLI/GLIB) and to determine whether combination of Sulfonylureas had clinically remarkable benefit over Metformin alone (MET) in patients with Type 2 Diabetes. This was a single centric, open labelled, prospective study, involving 70 Type 2 diabetes patients betweenage group of 18-75 yearsold. Data of only Type 2 diabetic patients who were prescribed either Metformin 500 mg,Metformin plus Glimepiride (500+2) mg and Metformin plus Glibenclamide (500+5) mg were included in the study. Efficacy was evaluated based on changes in RBS and FBS at every follow-up of one month for totally 3 months. Total of 70 patients were enrolled in the study but 6 patients lost follow up in MET Group and 2 patients in MET + GLI Group. Therefore 24 patients in MET, 18 patients in MET + GLI group and 20 patients in MET + GLI group completed study. A statistically significant reduction in RBS and FBS was seen in all the groups. MET + GLI treatment showed a statistically significant reduction in RBS at third month as compared to other groups.Study demonstrated that combination of Metformin+Glimepiridetreatment was more effective than Metformin+Glibenclamide and Metformin alone in reducing Fasting blood sugar and Random blood sugar. Thus Combination therapy of Metformin with Glimepiride seems to be a better treatment in patients having Type 2 diabetes.